Antiemetic Activity of FK1052, a 5-HT3- and 5-HT4-Receptor Antagonist, in Suncus murinus and Ferrets
We investigated the effect of FK1052 [(+)-8,9-dihydro-10-methyl-7-[(5-methyl-1H-imidazol-4-yl)methyl]pyrido[1,2-a]indol-6(7H)-one hydrochloride], a 5-HT3- and 5-HT4-receptor antagonist, on the emesis induced by motion stimuli, copper sulfate, or cisplatin in either Suncus murinus or ferrets and also...
Saved in:
| Published in | Journal of Pharmacological Sciences Vol. 98; no. 4; pp. 396 - 403 |
|---|---|
| Main Authors | , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Japan
Elsevier B.V
2005
The Japanese Pharmacological Society Elsevier |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | We investigated the effect of FK1052 [(+)-8,9-dihydro-10-methyl-7-[(5-methyl-1H-imidazol-4-yl)methyl]pyrido[1,2-a]indol-6(7H)-one hydrochloride], a 5-HT3- and 5-HT4-receptor antagonist, on the emesis induced by motion stimuli, copper sulfate, or cisplatin in either Suncus murinus or ferrets and also clarified the role of the 5-HT3 and 5-HT4 receptors in these models. In Suncus murinus, oral administration of FK1052 (100 µg/kg) completely prevented emesis induced by cisplatin (18 mg/kg, i.p.). Intraperitoneal injection of scopolamine (10 mg/kg) and promethazine (32 mg/kg), but not FK1052 (1 mg/kg), significantly reduced the emetic responses by motion stimuli. In ferrets, copper sulfate (40 mg/kg, p.o.)-induced emesis was moderately prevented by FK1052 (3.2 mg/kg), but not by granisetron (3.2 mg/kg). Cisplatin-induced acute (10 mg/kg, i.v.) and delayed (5 mg/kg, i.p.) emesis were significantly reduced by single and multiple intravenous injection of both FK1052 (3.2 mg/kg) and granisetron (3.2 mg/kg), respectively. The present study suggests that FK1052 may be useful against both acute and delayed emesis induced by cancer chemotherapy. Moreover, it is suggested that blockades of 5-HT3 and 5-HT4 receptors are not relevant to the control of motion sickness; and furthermore, it suggested that blocking 5-HT4 receptors in addition to 5-HT3 receptors does not have an additional effect on the control of cisplatin-induced emesis, but that 5-HT4 receptors are at least partly involved in the mechanism of emesis induced by copper sulfate. |
|---|---|
| AbstractList | We investigated the effect of FK1052 [(+)-8,9-dihydro-10-methyl-7-[(5-methyl-1H-imidazol-4-yl)methyl]pyrido[1,2-a]indol-6(7H)-one hydrochloride], a 5-HT3- and 5-HT4-receptor antagonist, on the emesis induced by motion stimuli, copper sulfate, or cisplatin in either Suncus murinus or ferrets and also clarified the role of the 5-HT3 and 5-HT4 receptors in these models. In Suncus murinus, oral administration of FK1052 (100 µg/kg) completely prevented emesis induced by cisplatin (18 mg/kg, i.p.). Intraperitoneal injection of scopolamine (10 mg/kg) and promethazine (32 mg/kg), but not FK1052 (1 mg/kg), significantly reduced the emetic responses by motion stimuli. In ferrets, copper sulfate (40 mg/kg, p.o.)-induced emesis was moderately prevented by FK1052 (3.2 mg/kg), but not by granisetron (3.2 mg/kg). Cisplatin-induced acute (10 mg/kg, i.v.) and delayed (5 mg/kg, i.p.) emesis were significantly reduced by single and multiple intravenous injection of both FK1052 (3.2 mg/kg) and granisetron (3.2 mg/kg), respectively. The present study suggests that FK1052 may be useful against both acute and delayed emesis induced by cancer chemotherapy. Moreover, it is suggested that blockades of 5-HT3 and 5-HT4 receptors are not relevant to the control of motion sickness; and furthermore, it suggested that blocking 5-HT4 receptors in addition to 5-HT3 receptors does not have an additional effect on the control of cisplatin-induced emesis, but that 5-HT4 receptors are at least partly involved in the mechanism of emesis induced by copper sulfate. Keywords:: motion sickness, cisplatin, acute emesis, delayed emesis, copper sulfate We investigated the effect of FK1052 [(+)-8,9-dihydro-10-methyl-7-[(5-methyl-1H-imidazol-4-yl)methyl]pyrido[1,2-a]indol-6(7H)-one hydrochloride], a 5-HT3- and 5-HT4-receptor antagonist, on the emesis induced by motion stimuli, copper sulfate, or cisplatin in either Suncus murinus or ferrets and also clarified the role of the 5-HT3 and 5-HT4 receptors in these models. In Suncus murinus, oral administration of FK1052 (100 μg/kg) completely prevented emesis induced by cisplatin (18 mg/kg, i.p.). Intraperitoneal injection of scopolamine (10 mg/kg) and promethazine (32 mg/kg), but not FK1052 (1 mg/kg), significantly reduced the emetic responses by motion stimuli. In ferrets, copper sulfate (40 mg/kg, p.o.)-induced emesis was moderately prevented by FK1052 (3.2 mg/kg), but not by granisetron (3.2 mg/kg). Cisplatin-induced acute (10 mg/kg, i.v.) and delayed (5 mg/kg, i.p.) emesis were significantly reduced by single and multiple intravenous injection of both FK1052 (3.2 mg/kg) and granisetron (3.2 mg/kg), respectively. The present study suggests that FK1052 may be useful against both acute and delayed emesis induced by cancer chemotherapy. Moreover, it is suggested that blockades of 5-HT3 and 5-HT4 receptors are not relevant to the control of motion sickness; and furthermore, it suggested that blocking 5-HT4 receptors in addition to 5-HT3 receptors does not have an additional effect on the control of cisplatin-induced emesis, but that 5-HT4 receptors are at least partly involved in the mechanism of emesis induced by copper sulfate. We investigated the effect of FK1052 [(+)-8,9-dihydro-10-methyl-7-[(5-methyl-1H-imidazol-4-yl)methyl]pyrido[1,2-a]indol-6(7H)-one hydrochloride], a 5-HT3- and 5-HT4-receptor antagonist, on the emesis induced by motion stimuli, copper sulfate, or cisplatin in either Suncus murinus or ferrets and also clarified the role of the 5-HT3 and 5-HT4 receptors in these models. In Suncus murinus, oral administration of FK1052 (100 µg/kg) completely prevented emesis induced by cisplatin (18 mg/kg, i.p.). Intraperitoneal injection of scopolamine (10 mg/kg) and promethazine (32 mg/kg), but not FK1052 (1 mg/kg), significantly reduced the emetic responses by motion stimuli. In ferrets, copper sulfate (40 mg/kg, p.o.)-induced emesis was moderately prevented by FK1052 (3.2 mg/kg), but not by granisetron (3.2 mg/kg). Cisplatin-induced acute (10 mg/kg, i.v.) and delayed (5 mg/kg, i.p.) emesis were significantly reduced by single and multiple intravenous injection of both FK1052 (3.2 mg/kg) and granisetron (3.2 mg/kg), respectively. The present study suggests that FK1052 may be useful against both acute and delayed emesis induced by cancer chemotherapy. Moreover, it is suggested that blockades of 5-HT3 and 5-HT4 receptors are not relevant to the control of motion sickness; and furthermore, it suggested that blocking 5-HT4 receptors in addition to 5-HT3 receptors does not have an additional effect on the control of cisplatin-induced emesis, but that 5-HT4 receptors are at least partly involved in the mechanism of emesis induced by copper sulfate. We investigated the effect of FK1052 [(+)-8,9-dihydro-10-methyl-7-[(5-methyl-1H-imidazol-4-yl)methyl]pyrido[1,2-a]indol-6(7H)-one hydrochloride], a 5-HT3- and 5-HT4-receptor antagonist, on the emesis induced by motion stimuli, copper sulfate, or cisplatin in either Suncus murinus or ferrets and also clarified the role of the 5-HT3 and 5-HT4 receptors in these models. In Suncus murinus, oral administration of FK1052 (100 microg/kg) completely prevented emesis induced by cisplatin (18 mg/kg, i.p.). Intraperitoneal injection of scopolamine (10 mg/kg) and promethazine (32 mg/kg), but not FK1052 (1 mg/kg), significantly reduced the emetic responses by motion stimuli. In ferrets, copper sulfate (40 mg/kg, p.o.)-induced emesis was moderately prevented by FK1052 (3.2 mg/kg), but not by granisetron (3.2 mg/kg). Cisplatin-induced acute (10 mg/kg, i.v.) and delayed (5 mg/kg, i.p.) emesis were significantly reduced by single and multiple intravenous injection of both FK1052 (3.2 mg/kg) and granisetron (3.2 mg/kg), respectively. The present study suggests that FK1052 may be useful against both acute and delayed emesis induced by cancer chemotherapy. Moreover, it is suggested that blockades of 5-HT3 and 5-HT4 receptors are not relevant to the control of motion sickness; and furthermore, it suggested that blocking 5-HT4 receptors in addition to 5-HT3 receptors does not have an additional effect on the control of cisplatin-induced emesis, but that 5-HT4 receptors are at least partly involved in the mechanism of emesis induced by copper sulfate.We investigated the effect of FK1052 [(+)-8,9-dihydro-10-methyl-7-[(5-methyl-1H-imidazol-4-yl)methyl]pyrido[1,2-a]indol-6(7H)-one hydrochloride], a 5-HT3- and 5-HT4-receptor antagonist, on the emesis induced by motion stimuli, copper sulfate, or cisplatin in either Suncus murinus or ferrets and also clarified the role of the 5-HT3 and 5-HT4 receptors in these models. In Suncus murinus, oral administration of FK1052 (100 microg/kg) completely prevented emesis induced by cisplatin (18 mg/kg, i.p.). Intraperitoneal injection of scopolamine (10 mg/kg) and promethazine (32 mg/kg), but not FK1052 (1 mg/kg), significantly reduced the emetic responses by motion stimuli. In ferrets, copper sulfate (40 mg/kg, p.o.)-induced emesis was moderately prevented by FK1052 (3.2 mg/kg), but not by granisetron (3.2 mg/kg). Cisplatin-induced acute (10 mg/kg, i.v.) and delayed (5 mg/kg, i.p.) emesis were significantly reduced by single and multiple intravenous injection of both FK1052 (3.2 mg/kg) and granisetron (3.2 mg/kg), respectively. The present study suggests that FK1052 may be useful against both acute and delayed emesis induced by cancer chemotherapy. Moreover, it is suggested that blockades of 5-HT3 and 5-HT4 receptors are not relevant to the control of motion sickness; and furthermore, it suggested that blocking 5-HT4 receptors in addition to 5-HT3 receptors does not have an additional effect on the control of cisplatin-induced emesis, but that 5-HT4 receptors are at least partly involved in the mechanism of emesis induced by copper sulfate. We investigated the effect of FK1052 [(+)-8,9-dihydro-10-methyl-7-[(5-methyl-1H-imidazol-4-yl)methyl]pyrido[1,2-a]indol-6(7H)-one hydrochloride], a 5-HT3- and 5-HT4-receptor antagonist, on the emesis induced by motion stimuli, copper sulfate, or cisplatin in either Suncus murinus or ferrets and also clarified the role of the 5-HT3 and 5-HT4 receptors in these models. In Suncus murinus, oral administration of FK1052 (100 microg/kg) completely prevented emesis induced by cisplatin (18 mg/kg, i.p.). Intraperitoneal injection of scopolamine (10 mg/kg) and promethazine (32 mg/kg), but not FK1052 (1 mg/kg), significantly reduced the emetic responses by motion stimuli. In ferrets, copper sulfate (40 mg/kg, p.o.)-induced emesis was moderately prevented by FK1052 (3.2 mg/kg), but not by granisetron (3.2 mg/kg). Cisplatin-induced acute (10 mg/kg, i.v.) and delayed (5 mg/kg, i.p.) emesis were significantly reduced by single and multiple intravenous injection of both FK1052 (3.2 mg/kg) and granisetron (3.2 mg/kg), respectively. The present study suggests that FK1052 may be useful against both acute and delayed emesis induced by cancer chemotherapy. Moreover, it is suggested that blockades of 5-HT3 and 5-HT4 receptors are not relevant to the control of motion sickness; and furthermore, it suggested that blocking 5-HT4 receptors in addition to 5-HT3 receptors does not have an additional effect on the control of cisplatin-induced emesis, but that 5-HT4 receptors are at least partly involved in the mechanism of emesis induced by copper sulfate. |
| Author | Nakayama, Hiroe Mutoh, Seitaro Imazumi, Katsunori Higaki, Mika Yamakuni, Hisashi Matsuo, Masahiko Ishikawa, Hirofumi |
| Author_xml | – sequence: 1 givenname: Hiroe surname: Nakayama fullname: Nakayama, Hiroe organization: Medicinal Biology Research Laboratories, Fujisawa Pharmaceutical Co., Ltd., Kashima 2-1-6, Yodogawa-ku, Osaka 532-8514, Japan – sequence: 2 givenname: Hisashi surname: Yamakuni fullname: Yamakuni, Hisashi email: hisashi.yamakuni@jp.astellas.com organization: Medicinal Biology Research Laboratories, Fujisawa Pharmaceutical Co., Ltd., Kashima 2-1-6, Yodogawa-ku, Osaka 532-8514, Japan – sequence: 3 givenname: Mika surname: Higaki fullname: Higaki, Mika organization: New Drug Research Laboratories, Fujisawa Pharmaceutical Co., Ltd., Kashima 2-1-6, Yodogawa-ku, Osaka 532-8514, Japan – sequence: 4 givenname: Hirofumi surname: Ishikawa fullname: Ishikawa, Hirofumi organization: Medicinal Biology Research Laboratories, Fujisawa Pharmaceutical Co., Ltd., Kashima 2-1-6, Yodogawa-ku, Osaka 532-8514, Japan – sequence: 5 givenname: Katsunori surname: Imazumi fullname: Imazumi, Katsunori organization: Medicinal Biology Research Laboratories, Fujisawa Pharmaceutical Co., Ltd., Kashima 2-1-6, Yodogawa-ku, Osaka 532-8514, Japan – sequence: 6 givenname: Masahiko surname: Matsuo fullname: Matsuo, Masahiko organization: Medicinal Biology Research Laboratories, Fujisawa Pharmaceutical Co., Ltd., Kashima 2-1-6, Yodogawa-ku, Osaka 532-8514, Japan – sequence: 7 givenname: Seitaro surname: Mutoh fullname: Mutoh, Seitaro organization: Medicinal Biology Research Laboratories, Fujisawa Pharmaceutical Co., Ltd., Kashima 2-1-6, Yodogawa-ku, Osaka 532-8514, Japan |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/16079468$$D View this record in MEDLINE/PubMed |
| BookMark | eNp1Uk1v1DAQjVAR_YArR5QTp2axEzuxb6wqlhYqgaBI3CzHnrSOEjvYTkX_Pd5NGwkkLp7R-L03nnk-zY6ss5BlrzHa4JKSd_10Fzbd1COKEP79LDvBFWkKVhN2tOa4Os5OQ-gRKhnC9YvsGNeo4aRmJ5ne2mhghGhUvlXR3Jv4kLsu333GiJbnucxpcXlTFbm0-pCS4hsomKLzeaLKW2dNiOe5sfn32ao55OPsjU1xT9iB9xDDy-x5J4cArx7jWfZj9-Hm4rK4_vLx6mJ7Xaj0nlhQhRqimWQYc10C1brBnBFgFZUtB912VLVd1yAghLSobCitdaeRLkvV4IZXZ9nVoqud7MXkzSj9g3DSiEPB-VshfZp0AMEVwgCUUeCcKI5ZU1KADvNWUS55mbTeLlqTd79mCFGMJigYBmnBzUHUjCJMcZWAbx6BczuCXts-7TgByAJQ3oXgoRPKRBmNs9FLMwiMxN5KsbdS7L5-Olj5M9E2_9BW5f8R3i-EPiRfYIU_jXyAcybIclS8Xq_UnfQCbJJgiwQkl-4NeBGUAatAGw8qpjWav7uvP6_6AzFGym0 |
| CitedBy_id | crossref_primary_10_2131_jts_36_23 crossref_primary_10_1007_s43440_023_00514_z crossref_primary_10_1186_s40360_016_0110_9 crossref_primary_10_1254_jphs_SCJ05007X crossref_primary_10_1371_journal_pone_0060537 crossref_primary_10_1016_j_autneu_2006_02_011 crossref_primary_10_1097_FBP_0000000000000558 crossref_primary_10_1016_j_pbb_2013_08_012 crossref_primary_10_1016_j_brainres_2007_04_061 crossref_primary_10_1093_toxsci_kft033 crossref_primary_10_3389_fphys_2017_00412 crossref_primary_10_1517_13543784_2010_528388 crossref_primary_10_2131_jts_37_549 crossref_primary_10_1371_journal_pone_0124203 crossref_primary_10_1016_j_ejphar_2013_10_014 crossref_primary_10_1016_j_ddstr_2007_09_002 crossref_primary_10_3389_fphar_2016_00221 crossref_primary_10_1007_s00221_014_3954_5 crossref_primary_10_1021_cr900117p crossref_primary_10_1111_j_1742_7843_2008_00253_x crossref_primary_10_3390_jpm14080797 crossref_primary_10_1007_s11094_013_0968_4 crossref_primary_10_1007_s00280_010_1339_4 |
| Cites_doi | 10.1254/jphs.FPJ04035X 10.1016/0014-2999(96)00407-4 10.1016/0024-3205(88)90520-6 10.1016/S0091-3057(02)00955-3 10.1139/y90-040 10.1111/j.1476-5381.1996.tb15761.x 10.1159/000227644 10.1016/S0014-2999(99)00219-8 10.1016/0028-3908(94)90136-8 10.1254/jjp.85.70 10.1139/y90-047 10.1016/0014-2999(88)90503-1 10.1254/jjp.55.107 10.1016/0024-3205(87)90229-3 10.1254/jjp.64.109 10.1002/med.2610100404 10.1016/S0361-9230(98)00092-6 10.1016/0014-2999(91)90852-H |
| ContentType | Journal Article |
| Copyright | 2005 Elsevier B.V. The Japanese Pharmacological Society 2005 |
| Copyright_xml | – notice: 2005 Elsevier B.V. – notice: The Japanese Pharmacological Society 2005 |
| DBID | 6I. AAFTH AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 DOA |
| DOI | 10.1254/jphs.fpj05001x |
| DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1347-8648 |
| EndPage | 403 |
| ExternalDocumentID | oai_doaj_org_article_9c01ee585e994c918725eef19bc59a92 16079468 10_1254_jphs_FPJ05001X article_jphs_98_4_98_4_396_article_char_en S1347861319321553 |
| Genre | Journal Article Comparative Study |
| GroupedDBID | --- .55 .GJ 0R~ 0SF 29L 2WC 3O- 4.4 457 53G 5GY 5RE 6I. AACTN AAEDT AAEDW AAFTH AAIKJ AALRI AAXUO ABMAC ACGFO ACGFS ADBBV ADEZE AENEX AEXQZ AFTJW AGHFR AHPSJ AITUG AL- ALMA_UNASSIGNED_HOLDINGS AMRAJ BAWUL BCNDV BKOMP CS3 DIK DU5 E3Z EBS EJD F5P FDB GROUPED_DOAJ GX1 HH5 IPNFZ JMI JSF JSH KQ8 M41 MOJWN M~E NCXOZ O9- OK1 RIG RJT RNS ROL RZJ SSZ TKC TR2 W2D X7M XSB ZGI ZXP AAUGY AAYWO AAYXX ACVFH ADCNI ADVLN AEUPX AFJKZ AFPUW AIGII AKBMS AKRWK AKYEP APXCP CITATION OVT CGR CUY CVF ECM EIF NPM 7X8 |
| ID | FETCH-LOGICAL-c607t-5c074d8a8119d2e5dd71984e835ab9edbf5cbff70e444b027556dfd0d22c71793 |
| IEDL.DBID | DOA |
| ISSN | 1347-8613 |
| IngestDate | Wed Aug 27 00:41:07 EDT 2025 Fri Jul 11 07:15:17 EDT 2025 Sat Sep 28 08:37:30 EDT 2024 Thu Apr 24 23:04:19 EDT 2025 Tue Jul 01 01:26:52 EDT 2025 Thu Aug 17 20:30:31 EDT 2023 Fri Feb 23 02:27:12 EST 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 4 |
| Keywords | motion sickness delayed emesis cisplatin copper sulfate acute emesis |
| Language | English |
| License | http://creativecommons.org/licenses/by-nc-nd/4.0 |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c607t-5c074d8a8119d2e5dd71984e835ab9edbf5cbff70e444b027556dfd0d22c71793 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 |
| OpenAccessLink | https://doaj.org/article/9c01ee585e994c918725eef19bc59a92 |
| PMID | 16079468 |
| PQID | 68501513 |
| PQPubID | 23479 |
| PageCount | 8 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_9c01ee585e994c918725eef19bc59a92 proquest_miscellaneous_68501513 pubmed_primary_16079468 crossref_citationtrail_10_1254_jphs_FPJ05001X crossref_primary_10_1254_jphs_FPJ05001X jstage_primary_article_jphs_98_4_98_4_396_article_char_en elsevier_sciencedirect_doi_10_1254_jphs_fpj05001x |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2005 |
| PublicationDateYYYYMMDD | 2005-01-01 |
| PublicationDate_xml | – year: 2005 text: 2005 |
| PublicationDecade | 2000 |
| PublicationPlace | Japan |
| PublicationPlace_xml | – name: Japan |
| PublicationTitle | Journal of Pharmacological Sciences |
| PublicationTitleAlternate | J Pharmacol Sci |
| PublicationYear | 2005 |
| Publisher | Elsevier B.V The Japanese Pharmacological Society Elsevier |
| Publisher_xml | – name: Elsevier B.V – name: The Japanese Pharmacological Society – name: Elsevier |
| References | 11 Nagakura Y, Kadowaki M, Tokoro K, Tomoi M, Mori J, Kohsaka M. Pharmacological characterization of FK1052, a dihydropyridoindole derivative, as a new serotonin 3 and 4 dual receptor antagonist. J Pharmacol Exp Ther. 1993;265:752-758. 20 Dumuis A, Bouhelal R, Sebben M, Bockaert J. A 5-HT receptor in the central nervous system, positively coupled with adenylate cyclase, is antagonized by ICS 205-930. Eur J Pharmacol. 1988;146:187-188. 25 Rudd JA, Jordan CC, Naylor RJ. The action of the NK1 tachykinin receptor antagonist, CP 99,994, in antagonizing the acute and delayed emesis induced by cisplatin in the ferret. Br J Pharmacol. 1996;119:931-936. 12 Yamakuni H, Ito H, Ishikawa H, Sogabe H, Higaki M, Nagakura Y, et al. Effect of FK1052, a novel potent 5-hydroxytryptamine3 receptor antagonist, on cisplatin-induced emesis in dogs. Jpn J Pharmacol. 1992;58 Suppl 1:355P. 14 Okada F, Torii Y, Saito H, Matsuki N. Antiemetic effects of serotonergic 5-HT1A-receptor agonists in Suncus murinus. Jpn J Pharmacol. 1994;64:109-114. 16 Lucot BL, Crampton GH. Buspirone blocks motion sickness and xylazine-induced emesis in the cat. Aviat Space Environ Med. 1987;58:989-991. 27 Lucot BL, Crampton GH. Xylazine emesis, yohimbine and motion sickness susceptibility in the cat. J Pharmacol Exp Ther. 1986;237:450-455. 22 Andrews PLR, Davis CJ, Bingham S, Daividson HIM, Hawthorn J, Maskell L. The abdominal visceral innervation and the emetic reflex: Pathways, pharmacology, and plasticity. Can J Physiol Pharmacol. 1990;68:325-345. 18 Fukui H, Yamamoto M, Sasaki S, Sato S. Possible involvement of peripheral 5-HT4 receptors in copper sulfate-induced vomiting in dogs. Eur J Pharmacol. 1994;257:47-52. 9 Fukui H, Yamamoto M. Methotrexate produces delayed emesis in dogs: A potential model for delayed emesis induced by chemotherapy. Eur J Pharmacol. 1999;372:261-267. 17 Bhandari P, Andrews PLR. Preliminary evidence for the involvement of the putative 5-HT4 receptor in zacopride- and copper sulfate-induced vomiting in the ferret. Eur J Pharmacol. 1991;204:273-280. 1 King GL. Animal models in the study of vomiting. Can J Physiol Pharmacol. 1990;68:260-268. 24 Torii Y, Saito H, Matsuki N. Selective blockade of cytotoxic drug-induced emesis by 5-HT3 receptor antagonists in Suncus Murinus. Jpn J Pharmacol. 1991;55:107-113. 13 Yamakuni H, Sawai H, Maeda Y, Imazumi K, Sakuma H, Matsuo M, et al. Probable involvement of the 5-hydroxytryptamine4 receptor in methotrexate-induced delayed emesis in dogs. J Pharmacol Exp Ther. 2000;292:1002-1007. 2 Ueno S, Matsuki N, Saito H. Suncus murinus: a new experimental model in emesis research. Life Sci. 1988;41:513-518. 3 Kilpatrick GJ, Bunce KT, Tyers MB. 5-HT3 receptors. Med Res Rev. 1990;10:441-475. 8 Grelot L, Stunff HL, Milano S, Blower PR, Romain D. Repeated administration of the 5-HT3 receptor antagonist granisetron reduces the incidence of delayed cisplatin-induced emesis in the piglet. J Pharmacol Exp Ther. 1996;279:255-261. 21 Twissell DJ, Boutra C, Dale TJ, Gardner CJ, Jordan CC, Ward P. 5-HT4 receptors are not involved in the emetic response to cisplatin, copper sulfate and R,S-zacopride in the ferret. Br J Pharmacol. 1994;113:22P. 23 Horikoshi K, Yokoyama T, Kishibayashi N, Ohmori K, Ishii A, Karasawa A. Possible involvement of 5-HT4 receptors, in addition to 5-HT3 receptors, in the emesis induced by high-dose cisplatin in Suncus murinus. Jpn J Pharmacol. 2001;85:70-74. 5 Rudd JA, Jordan CC, Naylor RJ. Profiles of emetic action of cisplatin in the ferret: A potential model of acute and delayed emesis. Eur J Pharmacol. 1994;262:R1-R2. 15 Nakayama H, Yamakuni H, Nakayama A, Maeda Y, Imazumi K, Matsuo M, et al. Diphenidol has no actual broad antiemetic activity in dogs and ferrets. J Pharmacol Sci. 2004;96:301-306. 7 Rudd JA, Naylor RJ. Effects of 5-HT3 receptor antagonists on model of acute and delayed emesis induced by cisplatin in the ferret. Neuropharmacology. 1994;33:1607-1608. 28 Ueno S, Matsuki N, Saito H. Suncus murinus as a new experimental model for motion sickness. Life Sci. 1988;43:413-420. 10 Kadowaki M, Nagakura Y, Tomoi M, Mori J, Kohsaka M. Effect of FK1052, a potent 5-hydroxytryptamine3 and 5-hydroxytryptamine4 receptor dual antagonist, on colonic function in vivo. J Pharmacol Exp Ther. 1993;266:74-80. 4 Hesketh P. Management of cisplatin-induced delayed emesis. Oncology. 1996;53 Suppl 1:73-77. 26 Yates BJ, Miller AD, Lucot JB. Physiological basis and pharmacology of motion sickness. Brain Res Bull. 1998;47:395-406. 29 Javid FA, Naylor RJ. The effect of serotonin and serotonin receptor antagonists on motion sickness in Suncus murinus. Pharmacol Biochem Behav. 2002;73:979-989. 19 Okada F, Saito H, Matsuki N. Prophylactic effect of serotonin uptake inhibitors against motion sickness in Suncus murinus. Eur J Pharmacol. 1996;309:33-35. 6 Milano S, Blower P, Romain D, Grelot L. The piglet as a suitable animal model for studying the delayed phase cisplatin-induced emesis. J Pharmacol Exp Ther. 1995;274:951-961. 23 (22) 1990; 68 (27) 1986; 237 (10) 1993; 266 (25) 1996; 119 (3) 1990; 10 28 Lucot BL, Crampton GH (16) 1987; 58 YAMAKUNI H (13) 2000; 292 Twissell DJ, Boutra C, Dale TJ, Gardner CJ, Jordan CC, Ward P (21) 1994; 113 TORII Y (24) 1991; 55 Yamakuni H, Ito H, Ishikawa H, Sogabe H, Higaki M, Nagakura Y, et al (12) 1992; 58 (8) 1996; 279 (18) 1994; 257 (5) 1994; 262 OKADA F (14) 1994; 64 (6) 1995; 274 (1) 1990; 68 Ueno S, Matsuki N, Saito H (2) 1988; 41 15 17 19 (11) 1993; 265 Yates BJ, Miller AD, Lucot JB (26) 1998; 47 Javid FA, Naylor RJ (29) 2002; 73 Hesketh P (4) 1996; 53 7 9 20 |
| References_xml | – reference: 27 Lucot BL, Crampton GH. Xylazine emesis, yohimbine and motion sickness susceptibility in the cat. J Pharmacol Exp Ther. 1986;237:450-455. – reference: 19 Okada F, Saito H, Matsuki N. Prophylactic effect of serotonin uptake inhibitors against motion sickness in Suncus murinus. Eur J Pharmacol. 1996;309:33-35. – reference: 14 Okada F, Torii Y, Saito H, Matsuki N. Antiemetic effects of serotonergic 5-HT1A-receptor agonists in Suncus murinus. Jpn J Pharmacol. 1994;64:109-114. – reference: 25 Rudd JA, Jordan CC, Naylor RJ. The action of the NK1 tachykinin receptor antagonist, CP 99,994, in antagonizing the acute and delayed emesis induced by cisplatin in the ferret. Br J Pharmacol. 1996;119:931-936. – reference: 24 Torii Y, Saito H, Matsuki N. Selective blockade of cytotoxic drug-induced emesis by 5-HT3 receptor antagonists in Suncus Murinus. Jpn J Pharmacol. 1991;55:107-113. – reference: 29 Javid FA, Naylor RJ. The effect of serotonin and serotonin receptor antagonists on motion sickness in Suncus murinus. Pharmacol Biochem Behav. 2002;73:979-989. – reference: 16 Lucot BL, Crampton GH. Buspirone blocks motion sickness and xylazine-induced emesis in the cat. Aviat Space Environ Med. 1987;58:989-991. – reference: 28 Ueno S, Matsuki N, Saito H. Suncus murinus as a new experimental model for motion sickness. Life Sci. 1988;43:413-420. – reference: 9 Fukui H, Yamamoto M. Methotrexate produces delayed emesis in dogs: A potential model for delayed emesis induced by chemotherapy. Eur J Pharmacol. 1999;372:261-267. – reference: 4 Hesketh P. Management of cisplatin-induced delayed emesis. Oncology. 1996;53 Suppl 1:73-77. – reference: 20 Dumuis A, Bouhelal R, Sebben M, Bockaert J. A 5-HT receptor in the central nervous system, positively coupled with adenylate cyclase, is antagonized by ICS 205-930. Eur J Pharmacol. 1988;146:187-188. – reference: 11 Nagakura Y, Kadowaki M, Tokoro K, Tomoi M, Mori J, Kohsaka M. Pharmacological characterization of FK1052, a dihydropyridoindole derivative, as a new serotonin 3 and 4 dual receptor antagonist. J Pharmacol Exp Ther. 1993;265:752-758. – reference: 18 Fukui H, Yamamoto M, Sasaki S, Sato S. Possible involvement of peripheral 5-HT4 receptors in copper sulfate-induced vomiting in dogs. Eur J Pharmacol. 1994;257:47-52. – reference: 5 Rudd JA, Jordan CC, Naylor RJ. Profiles of emetic action of cisplatin in the ferret: A potential model of acute and delayed emesis. Eur J Pharmacol. 1994;262:R1-R2. – reference: 22 Andrews PLR, Davis CJ, Bingham S, Daividson HIM, Hawthorn J, Maskell L. The abdominal visceral innervation and the emetic reflex: Pathways, pharmacology, and plasticity. Can J Physiol Pharmacol. 1990;68:325-345. – reference: 6 Milano S, Blower P, Romain D, Grelot L. The piglet as a suitable animal model for studying the delayed phase cisplatin-induced emesis. J Pharmacol Exp Ther. 1995;274:951-961. – reference: 21 Twissell DJ, Boutra C, Dale TJ, Gardner CJ, Jordan CC, Ward P. 5-HT4 receptors are not involved in the emetic response to cisplatin, copper sulfate and R,S-zacopride in the ferret. Br J Pharmacol. 1994;113:22P. – reference: 15 Nakayama H, Yamakuni H, Nakayama A, Maeda Y, Imazumi K, Matsuo M, et al. Diphenidol has no actual broad antiemetic activity in dogs and ferrets. J Pharmacol Sci. 2004;96:301-306. – reference: 26 Yates BJ, Miller AD, Lucot JB. Physiological basis and pharmacology of motion sickness. Brain Res Bull. 1998;47:395-406. – reference: 7 Rudd JA, Naylor RJ. Effects of 5-HT3 receptor antagonists on model of acute and delayed emesis induced by cisplatin in the ferret. Neuropharmacology. 1994;33:1607-1608. – reference: 17 Bhandari P, Andrews PLR. Preliminary evidence for the involvement of the putative 5-HT4 receptor in zacopride- and copper sulfate-induced vomiting in the ferret. Eur J Pharmacol. 1991;204:273-280. – reference: 10 Kadowaki M, Nagakura Y, Tomoi M, Mori J, Kohsaka M. Effect of FK1052, a potent 5-hydroxytryptamine3 and 5-hydroxytryptamine4 receptor dual antagonist, on colonic function in vivo. J Pharmacol Exp Ther. 1993;266:74-80. – reference: 12 Yamakuni H, Ito H, Ishikawa H, Sogabe H, Higaki M, Nagakura Y, et al. Effect of FK1052, a novel potent 5-hydroxytryptamine3 receptor antagonist, on cisplatin-induced emesis in dogs. Jpn J Pharmacol. 1992;58 Suppl 1:355P. – reference: 2 Ueno S, Matsuki N, Saito H. Suncus murinus: a new experimental model in emesis research. Life Sci. 1988;41:513-518. – reference: 3 Kilpatrick GJ, Bunce KT, Tyers MB. 5-HT3 receptors. Med Res Rev. 1990;10:441-475. – reference: 1 King GL. Animal models in the study of vomiting. Can J Physiol Pharmacol. 1990;68:260-268. – reference: 8 Grelot L, Stunff HL, Milano S, Blower PR, Romain D. Repeated administration of the 5-HT3 receptor antagonist granisetron reduces the incidence of delayed cisplatin-induced emesis in the piglet. J Pharmacol Exp Ther. 1996;279:255-261. – reference: 13 Yamakuni H, Sawai H, Maeda Y, Imazumi K, Sakuma H, Matsuo M, et al. Probable involvement of the 5-hydroxytryptamine4 receptor in methotrexate-induced delayed emesis in dogs. J Pharmacol Exp Ther. 2000;292:1002-1007. – reference: 23 Horikoshi K, Yokoyama T, Kishibayashi N, Ohmori K, Ishii A, Karasawa A. Possible involvement of 5-HT4 receptors, in addition to 5-HT3 receptors, in the emesis induced by high-dose cisplatin in Suncus murinus. Jpn J Pharmacol. 2001;85:70-74. – volume: 262 start-page: R1 issn: 0014-2999 issue: 1/2 year: 1994 ident: 5 publication-title: Eur J Pharmacol – ident: 15 doi: 10.1254/jphs.FPJ04035X – volume: 266 start-page: 74 issn: 0022-3565 issue: 1 year: 1993 ident: 10 publication-title: J Pharmacol Exp Ther – volume: 237 start-page: 450 issn: 0022-3565 issue: 2 year: 1986 ident: 27 publication-title: J Pharmacol Exp Ther – ident: 19 doi: 10.1016/0014-2999(96)00407-4 – ident: 28 doi: 10.1016/0024-3205(88)90520-6 – volume: 73 start-page: 979 issn: 0091-3057 year: 2002 ident: 29 publication-title: Pharmacol Biochem Behav doi: 10.1016/S0091-3057(02)00955-3 – volume: 68 start-page: 260 issn: 0008-4212 issue: 2 year: 1990 ident: 1 publication-title: Can J Physiol Pharmacol doi: 10.1139/y90-040 – volume: 119 start-page: 931 issn: 0007-1188 issue: 5 year: 1996 ident: 25 publication-title: Br J Pharmacol doi: 10.1111/j.1476-5381.1996.tb15761.x – volume: 53 start-page: 73 issn: 0030-2414 year: 1996 ident: 4 publication-title: Oncology doi: 10.1159/000227644 – ident: 9 doi: 10.1016/S0014-2999(99)00219-8 – ident: 7 doi: 10.1016/0028-3908(94)90136-8 – volume: 257 start-page: 47 issn: 0014-2999 issue: 1/2 year: 1994 ident: 18 publication-title: Eur J Pharmacol – volume: 58 start-page: 355P issn: 0021-5198 year: 1992 ident: 12 publication-title: Jpn J Pharmacol – volume: 58 start-page: 989 issn: 0095-6562 year: 1987 ident: 16 publication-title: Aviat Space Environ Med – volume: 292 start-page: 1002 issn: 0022-3565 issue: 3 year: 2000 ident: 13 publication-title: J Pharmacol Exp Ther – ident: 23 doi: 10.1254/jjp.85.70 – volume: 68 start-page: 325 issn: 0008-4212 issue: 2 year: 1990 ident: 22 publication-title: Can J Physiol Pharmacol doi: 10.1139/y90-047 – volume: 265 start-page: 752 issn: 0022-3565 issue: 2 year: 1993 ident: 11 publication-title: J Pharmacol Exp Ther – ident: 20 doi: 10.1016/0014-2999(88)90503-1 – volume: 274 start-page: 951 issn: 0022-3565 issue: 2 year: 1995 ident: 6 publication-title: J Pharmacol Exp Ther – volume: 55 start-page: 107 issn: 0021-5198 issue: 1 year: 1991 ident: 24 publication-title: Jpn J Pharmacol doi: 10.1254/jjp.55.107 – volume: 41 start-page: 513 issn: 0024-3205 year: 1988 ident: 2 publication-title: Life Sci doi: 10.1016/0024-3205(87)90229-3 – volume: 64 start-page: 109 issn: 0021-5198 issue: 2 year: 1994 ident: 14 publication-title: Jpn J Pharmacol doi: 10.1254/jjp.64.109 – volume: 10 start-page: 441 issn: 0198-6325 issue: 4 year: 1990 ident: 3 publication-title: Med Res Rev doi: 10.1002/med.2610100404 – volume: 279 start-page: 255 issn: 0022-3565 issue: 1 year: 1996 ident: 8 publication-title: J Pharmacol Exp Ther – volume: 47 start-page: 395 issn: 0361-9230 year: 1998 ident: 26 publication-title: Brain Res Bull doi: 10.1016/S0361-9230(98)00092-6 – volume: 113 start-page: 22P issn: 0007-1188 year: 1994 ident: 21 publication-title: Br J Pharmacol – ident: 17 doi: 10.1016/0014-2999(91)90852-H |
| SSID | ssj0028016 |
| Score | 1.8402284 |
| Snippet | We investigated the effect of FK1052 [(+)-8,9-dihydro-10-methyl-7-[(5-methyl-1H-imidazol-4-yl)methyl]pyrido[1,2-a]indol-6(7H)-one hydrochloride], a 5-HT3- and... |
| SourceID | doaj proquest pubmed crossref jstage elsevier |
| SourceType | Open Website Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 396 |
| SubjectTerms | acute emesis Animals Antiemetics - pharmacology Cisplatin Copper Sulfate delayed emesis Female Ferrets Imidazoles - pharmacology Indoles - pharmacology Male Motion Sickness Receptors, Serotonin, 5-HT3 Receptors, Serotonin, 5-HT4 Serotonin Antagonists - pharmacology Shrews Vomiting - chemically induced Vomiting - physiopathology Vomiting - prevention & control |
| Title | Antiemetic Activity of FK1052, a 5-HT3- and 5-HT4-Receptor Antagonist, in Suncus murinus and Ferrets |
| URI | https://dx.doi.org/10.1254/jphs.fpj05001x https://www.jstage.jst.go.jp/article/jphs/98/4/98_4_396/_article/-char/en https://www.ncbi.nlm.nih.gov/pubmed/16079468 https://www.proquest.com/docview/68501513 https://doaj.org/article/9c01ee585e994c918725eef19bc59a92 |
| Volume | 98 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| ispartofPNX | Journal of Pharmacological Sciences, 2005, Vol.98(4), pp.396-403 |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lj9MwELbQnrggWF7hsfiAlkvDxomd2MeCiKpFoEp0pd4ixx4vrdi0Iq20--8ZO4_Sw4oLlyRKnDjJjGe-sT2fCXlfY0xgObZvC4ABSs2yWLsE4jwxWVEAFA58cvK37_nsil8uxfKvpb78nLCOHrj7cRfKJAwAQS0oxY1iskgFgGOqNkJpFawv-rwhmOpDLbS7Ia8o42iD0WP1dI0YDV2stz_bj267TgRa6NsjdxRY-4-90hox2jXcDz-DGyofk0c9fqTT7r2fkAfQnJLzeUdAfTehi0M-VTuh53R-oKa-e0rstNmt4MYnLtKp6RaOoBtHy68IgNIJ1VTEs0UWU93YcMhjxJWwxcCc4q36euOJdid01dAf6BD3Lb3xvfW49zeU4Kf9ts_IVfll8XkW9-ssxCZPil0sDOIIK7VkTNkUhLUFU5IDgjNdK7C1E6Z2rkiAc177cU6Ur7OJTVNT-Ab-nJw0mwZeEspqnRsprdWp49oajQARYyqpPS1dwVhE4uF3V6YnIfdrYfyqfDCC4qm8eKpyfhnEs4zIh7H8tqPfuLfkJy-9sZSnzQ4nUJmqXpmqfylTRNgg-6pHIB2ywEetjiseNSgiqlOSseqhtlBOyYp3m0zl4yWfUod2KSLvBr2qsFn7sRrdwGbfVrkUCNRYFpEXnbodPh9lpnguX_2PD35NHgYu2tCn9Iac7H7v4S2irF19FhrUmfd04g89KiVH |
| linkProvider | Directory of Open Access Journals |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Antiemetic+Activity+of+FK1052%2C+a+5-HT3-+and+5-HT4-Receptor+Antagonist%2C+in+Suncus+murinus+and+Ferrets&rft.jtitle=Journal+of+Pharmacological+Sciences&rft.au=Nakayama%2C+Hiroe&rft.au=Yamakuni%2C+Hisashi&rft.au=Higaki%2C+Mika&rft.au=Ishikawa%2C+Hirofumi&rft.date=2005&rft.pub=The+Japanese+Pharmacological+Society&rft.issn=1347-8613&rft.eissn=1347-8648&rft.volume=98&rft.issue=4&rft.spage=396&rft.epage=403&rft_id=info:doi/10.1254%2Fjphs.FPJ05001X&rft.externalDocID=article_jphs_98_4_98_4_396_article_char_en |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1347-8613&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1347-8613&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1347-8613&client=summon |